The oncology diagnostics startup has approached SoftBank and Mubadala for funding, eight months after raising $900m.
Grail, a US-based oncology diagnostics spinout of genomics technology provider Illumina, is seeking funding from investors including telecommunications group SoftBank, CNBC reported yesterday.
The company has also approached multiple sovereign wealth funds, though only Abu Dhabi’s Mubadala Development Company was identified as a potential investor in the round, which would follow $900m in series B capital raised by Grail in March this year.
Grail is targeting a final close of more than $1bn for the series B round…
